Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Bell Potter Healthcare Conference 2022
24 slides from Rhythm Biosciences's conference presentation, Nov 9, 2022
Slide 1: Bell Potter Healthcare Conference Investor Presentation
For personal use only Bell Potter Healthcare Conference Investor Presentation 9 November 2022 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: Introduction
Introduction For personal use only Rhythm’s initial product, ColoSTAT® is a simple, affordable and highly accurate blood test for the detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. Market-ready with operational revenue
Slide 4: ColoSTAT Highlights
ColoSTAT® Highlights For personal use only Disruptive and transformative technology More affordable and easier to administer Globally addressable markets Performance better than market standard Manufacturing & Patents secured Operational revenues expected in FY’23 Platform Technology Extension Under
Slide 5: Company Overview
Company Overview For personal use only Capital Structure Share Price Chart ASX Code RHY $7,000,000 $2.50 $6,000,000 Share Price (at 7 November 2022) $1.12 $2.00 $5,000,000 Shares on Issue 216.7 M $1.50 $4,000,000 Unlisted Options 16.8 M $3,000,000 $1.00 Market Capitalisation $242.7 M $2,000,000 $0.5
Slide 6: Colorectal Cancer (CRC)
Colorectal Cancer (CRC) For personal use only COLORECTAL CANCER RISK FACTORS Globally, Colorectal Cancer is currently the 3rd largest cancer by volume with 1.93 million new cases diagnosed annually and 2nd largest cause of cancer related deaths AUSTRALIAN OPPORTUNITY “The National Bowel Cancer Scree
Slide 7: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market For personal use only US$39 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States
Slide 8: Poor acceptability of faecal tests limits CRC screening performance
Poor acceptability of faecal tests is a significant limitation to the performance of current CRC screening For personal use only Patients report inconvenience of sample collection, aversion with the procedure and general fear as significant barriers to CRC screening1-3 An observational study1 in ove
Slide 9: Current CRC screening involves a faecal test followed by colonoscopy
Current CRC screening involves the use of a faecal test followed by colonoscopy For personal use only Abbreviations: CRC, colorectal cancer; FIT, faecal test The FIT pathway consists of a cumbersome multi-step screening process which has a number of limitations1-2: • Self-administered test involving
Slide 10: ColoSTAT - Patient Friendly, Increased Compliance
ColoSTAT® - Patient Friendly, Increased Compliance For personal use only Early detection is the key to survival and reducing the cost of treatment Simple & Routine Patient Journey With ColoSTAT® ColoSTAT® has the potential to: Government screen / GP referral / patient ✓Improve participation in reque
Slide 11: Blood-based tests are preferred by patients over FIT
Blood-based tests, such as ColoSTAT®, are preferred by patients over FIT as they provide a more acceptable way to participate in testing For personal use only Blood-based tests are preferred over faecal tests (FIT) by 78–93% of people who are offered CRT testing1-5, with ease and convenience being t
Slide 12: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? For personal use only Unlike the FIT, ColoSTAT® is specific for colorectal cancer – not just blood in faeces. How it works ColoSTAT® Technology Sample Result Low cost assay format which is designed to integrate with existing pathology lab infrastructure. Col
Slide 13: ColoSTAT Performance
ColoSTAT® Performance For personal use only ColoSTAT® is expected to increase participation, leading to earlier detection and avoiding costly treatments ColoSTAT® Sensitivity Performance Comparison • Highly Accurate ColoSTAT® was shown to be 35% more accurate at detecting colorectal cancer than the
Slide 14: Missed early-stage CRC detection leads to costly healthcare
Missed detection of early-stage CRC leads to the use of costly healthcare for advanced disease For personal use only Colorectal cancer is associated with high healthcare costs which increase with advanced disease stage at diagnosis1-4 In Australia, the estimated annual cost of The symptoms of CRC on
Slide 15: Market Likely To Expand Significantly
Market Likely To Expand Significantly For personal use only ✓ USA Preventative Services Task Force recommends Colorectal Cancer Screening to commence at age 45. Five years younger than it previously recommended, adding circa 20 million patients to the screening population in the USA alone. ✓ Reducti
Slide 16: Australia – Growth of CRC in younger age groups
Australia – Growth of CRC in younger age groups For personal use only 25 – 29 years old 30 – 34 years old 35 – 39 years old 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 7 7 8 8 8 9 9 9 10 10 10 11
Slide 17: Unique Opportunity To Add Significant Value
Unique Opportunity To Add Significant Value For personal use only Seamless alignment across the entire value chain providing broader benefits for the health system Blood test is the Patients preferred testing method. Increased participation in screening. Cheaper testing leads to More lives saved. Re
Slide 18: Competitive Landscape – ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage For personal use only Blood based Epigenomics Novigenix Volition Rx Epi proColon® Colox® Nu.q™ Rhythm ColoSTAT® ~$300 per ~$150 per ~$430 per test test $ TBC test Clinical Genomics Colvera™ ~$400 per test ColoSTAT®’s comparative low cost & simplicity len
Slide 19: Competitive Landscape – ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage For personal use only Chart Title 100% 92% 93% 92% 91% 90% 81% 80% 78% 70% 68% 72% Performance / accuracy 60% of ColoSTAT® versus 50% other more expensive, 40% 30% competitor, blood-based 20% tests 10% 0% Colox Colvera Epi proColon ColoSTAT (Study 7) Sen
Slide 20: Market Entry Strategy
Market Entry Strategy For personal use only Rhythm’s strategy is underpinned by: ✓ Proven technology ✓ Global manufacturing capability ✓ Establish partner networks ✓ Secure commercialisation pathway/s ✓ Partnerships in various global jurisdictions ✓ USA – Two mainstream pathways: ✓ Lab Developed Tes
Slide 21: Platform Technology Expansion
Platform Technology Expansion For personal use only • The expansion program is expected to be significantly shortened, leveraging the Company’s lead biomarker which exhibits pan-cancerous properties; • A platform expansion program identified a number of additional cancer target markets that have for
Slide 22: Global Market Opportunity – Platform Expansion
Global Market Opportunity – Platform Expansion For personal use only Cancer Incidence Addressable Market Opportunity Number of global new cases and deaths in 2020, both sexes, all ages Screening Eligibility by Market [# people] Potential Screening Population Market Value [US$] Breast 2,261,419 US 75
Slide 23: Milestones Delivered and Future Catalysts
Milestones Delivered and Future Catalysts For personal use only Completion of Core CE Mark TGA Inclusion of Clinical trial Commenced the ColoSTAT® technology (Europe) and Submission RHY into the All (Study 7) Platform prototype test- technically expanded to UK (Australia) Ordinaries Index successful
Slide 24: Glenn Gilbert, CEO and Managing Director
For personal use only Glenn Gilbert CEO and Managing Director, Rhythm Biosciences [email protected] +61 3 8256 2880 www.rhythmbio.com 24
Rhythm Biosciences — Bell Potter Healthcare Conference 2022 on 6ix